EL 📈 EssilorLuxottica S. A. - Overview
Exchange: PA • Country: France • Currency: EUR • Type: Common Stock • ISIN: FR0000121667
EL: Lenses, Frames, Sunglasses, Equipment, Instruments, Eyewear
EssilorLuxottica S.A. is a global leader in the design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses, with a presence in Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and North America. The company operates through two main segments: Professional Solutions and Direct to Consumer, catering to the diverse needs of eyecare professionals, opticians, and consumers. Its extensive portfolio of brands includes Essilor, Varilux, Crizal, and Eyezen, among others, offering a wide range of lens solutions. Additionally, the company provides high-quality frames and sunglasses under renowned brands such as Ray-Ban, Oakley, and Persol.
The company's product offerings extend beyond lenses and frames to include finishing equipment, vision performance screening tools, and small instruments and consumables under the Essilor Instruments brand. It also provides advanced technology and equipment for optical surfacing, polishing, measuring, coating, and finishing under the Satisloh brand. Furthermore, EssilorLuxottica designs, develops, and markets lens edging and mounting instruments for opticians and prescription laboratories, as well as optometry instruments for eyecare professionals and institutions. Its products are distributed through a network of independent opticians, distributors, and large retail chains, as well as directly to consumers through its brick and mortar stores and online channels.
EssilorLuxottica's history dates back to 1849, and it has evolved significantly over the years, with a name change from Essilor International Société Anonyme to EssilorLuxottica Société Anonyme in October 2018. The company is headquartered in Paris, France, and its shares are listed under the ISIN code FR0000121667. As a common stock, it falls under the GICS Sub Industry category of Health Care Equipment. With a strong online presence, including its website at https://www.essilorluxottica.com, the company continues to innovate and expand its offerings to meet the growing demands of the eyecare and eyewear industry.
Additional Sources for EL Stock
EL Stock Overview
Market Cap in USD | 110,882m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception |
EL Stock Ratings
Growth 5y | 70.7% |
Fundamental | 73.5% |
Dividend | 62.1% |
Rel. Strength Industry | 4498 |
Analysts | - |
Fair Price Momentum | 246.39 EUR |
Fair Price DCF | 315.35 EUR |
EL Dividends
Dividend Yield 12m | 1.70% |
Yield on Cost 5y | 3.00% |
Annual Growth 5y | 27.99% |
Payout Consistency | 98.0% |
EL Growth Ratios
Growth Correlation 3m | 85.8% |
Growth Correlation 12m | 89.6% |
Growth Correlation 5y | 91.1% |
CAGR 5y | 11.86% |
CAGR/Mean DD 5y | 1.21 |
Sharpe Ratio 12m | 1.22 |
Alpha | 9.93 |
Beta | 0.63 |
Volatility | 16.27% |
Current Volume | 516.9k |
Average Volume 20d | 416.7k |
As of January 07, 2025, the stock is trading at EUR 233.00 with a total of 516,872 shares traded.
Over the past week, the price has changed by +0.30%, over one month by +1.04%, over three months by +9.70% and over the past year by +28.75%.
Yes, based on ValueRay Fundamental Analyses, EssilorLuxottica S. A. (PA:EL) is currently (January 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 73.53 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EL as of January 2025 is 246.39. This means that EL is currently overvalued and has a potential downside of 5.75%.
EssilorLuxottica S. A. has no consensus analysts rating.
According to ValueRays Forecast Model, EL EssilorLuxottica S. A. will be worth about 269.4 in January 2026. The stock is currently trading at 233.00. This means that the stock has a potential upside of +15.64%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 222.6 | -4.5% |
Analysts Target Price | - | - |
ValueRay Target Price | 269.4 | 15.6% |